A nonlinear optical material is represented by the following formula (1).

##STR00001##

A method for preparing a complex comprising a radioisotope of gallium for use in radiotherapy or in a medical imaging procedure, said method comprising adding a gallium radioisotope solution obtained directly from a gallium radionuclide generator to a composition comprising a pharmaceutically acceptable buffer and optionally also a pharmaceutically acceptable basic reagent, in amounts sufficient to increase the pH to a level in the range of 3 to 8, wherein the composition further comprises a chelator that is able to chelate radioactive gallium within said pH range and at moderate temperature, said chelator being optionally linked to a biological targeting agent. Kits and compositions for use in the method are also described and claimed.

A method for preparing a complex comprising a radioisotope of gallium for use in radiotherapy or in a medical imaging procedure, said method comprising adding a gallium radioisotope solution obtained directly from a gallium radionuclide generator to a composition comprising a pharmaceutically acceptable buffer and optionally also a pharmaceutically acceptable basic reagent, in amounts sufficient to increase the pH to a level in the range of 3 to 8, wherein the composition further comprises a chelator that is able to chelate radioactive gallium within said pH range and at moderate temperature, said chelator being optionally linked to a biological targeting agent. Kits and compositions for use in the method are also described and claimed.

This invention relates to compounds of formula 1, 2 or 3 ##STR00001##
a pharmaceutically acceptable salt, or solvate thereof, wherein X.sub.1, Y, R.sub.1, R.sub.2, R.sub.3, R.sub.4, and R.sub.5 are as defined herein. The compounds are antimicrobial agents that may be used to treat various bacterial and protozoal infections and disorders related to such infections. The invention also relates to pharmaceutical compositions containing the compounds and to methods of treating bacterial and protozoal infections by administering the compounds of formula 1, 2 or 3.

This invention relates to compounds of formula 1, 2 or 3 ##STR00001##
a pharmaceutically acceptable salt, or solvate thereof, wherein X.sub.1, Y, R.sub.1, R.sub.2, R.sub.3, R.sub.4, and R.sub.5 are as defined herein. The compounds are antimicrobial agents that may be used to treat various bacterial and protozoal infections and disorders related to such infections. The invention also relates to pharmaceutical compositions containing the compounds and to methods of treating bacterial and protozoal infections by administering the compounds of formula 1, 2 or 3.

A nonlinear optical material is represented by the following formula (1). At least one selected from the group consisting of R.sup.1 to R.sup.5, at least one selected from the group consisting of R.sup.6 to R.sup.10, and at least one selected from the group consisting of R.sup.11 to R.sup.15 are represented by the following formula (2).

##STR00001##

A composition for detecting an acidic compound and a method using the same are discloses herein. In some embodiments, the method includes contacting a composition comprising a metal-organic hybrid structure formed by coordinate bond between a compound represented by the following Chemical Formula 1 or a salt thereof and a metal ion, with an acidic compound to be detected, wherein the composition is in the form of a metallogel prior to contact with the acidic compound, and detecting the acidic compound based on the transition of the composition from the form of a metallogel to a liquid phase. In some embodiments, detection of the acidic compound can be visually confirmed by phase transformation of the composition from a metallogel to a liquid phase.

A composition for detecting an acidic compound and a method using the same are discloses herein. In some embodiments, the method includes contacting a composition comprising a metal-organic hybrid structure formed by coordinate bond between a compound represented by the following Chemical Formula 1 or a salt thereof and a metal ion, with an acidic compound to be detected, wherein the composition is in the form of a metallogel prior to contact with the acidic compound, and detecting the acidic compound based on the transition of the composition from the form of a metallogel to a liquid phase. In some embodiments, detection of the acidic compound can be visually confirmed by phase transformation of the composition from a metallogel to a liquid phase.

Novel Halogenated Benzylidine derivatives are provided which exhibit activity for the treatment of immunological diseases and inflammation

Novel Halogenated Benzylidine derivatives are provided which exhibit activity for the treatment of immunological diseases and inflammation